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ABSTRACT
Malignant gliomas have poor prognosis and urgently require new therapies. 
Activating Transcription Factor 5 (ATF5) is highly expressed in gliomas, and 
interference with its expression/function precipitates targeted glioma cell apoptosis 
in vitro and in vivo. We designed a novel deliverable truncated-dominant-negative 
(d/n) form of ATF5 fused to a cell-penetrating domain (Pen-d/n-ATF5-RP) that can be 
intraperitoneally/subcutaneously administered to mice harboring malignant gliomas 
generated; (1) by PDGF-B/sh-p53 retroviral transformation of endogenous neural 
progenitor cells; and (2) by human U87-MG xenografts. In vitro Pen-d/n-ATF5-RP 
entered into glioma cells and triggered massive apoptosis. In vivo, subcutaneously-
administered Pen-d/n-ATF5-RP passed the blood brain barrier, entered normal 
brain and tumor cells, and then caused rapid selective tumor cell death. MRI verified 
elimination of retrovirus-induced gliomas within 8-21 days. Histopathology revealed 
growth-suppression of intracerebral human U87-MG cells xenografts. For endogenous 
PDGF-B gliomas, there was no recurrence or mortality at 6-12 months versus 66% 
mortality in controls at 6 months. Necropsy and liver-kidney blood enzyme analysis 
revealed no adverse effects on brain or other tissues. Our findings thus identify Pen-
d/n-ATF5-RP as a potential therapy for malignant gliomas.
INTRODUCTION
Gliomas are the most common primary malignant 
brain tumors and many are, or develop to become, 
particularly invasive. Despite advances, there has been 
limited progress in improving patient outcomes and for 
this reason additional effective treatment approaches are 
urgently needed [1, 2]. Activating transcription factor 
5 (ATF5; activating transcription factor/CREB family 
member) is a potential target for treatment of gliomas [3-
6]. ATF5 is highly expressed in human glioblastomas [3] 
with expression levels reported to inversely correlate with 
disease prognosis [6, 7]. Gliomas are thought to arise from 
several cell origins. It is additionally relevant that ATF5 is 
also expressed by neural and glial progenitor cells [8-10], 
CD133+ glioma stem cells [11], and by stem cells isolated 
from human glioblastomas [6].
Interference with ATF5 function by a dominant 
negative-form of the protein promotes massive apoptosis of 
glioblastoma cells in vitro and in vivo without detrimental 
effect on normal cells [3, 4, 8-10, 12]. ATF5 silencing 
with siRNA in vitro achieved similar results, indicating 
that these effects were due to ATF5 loss-of-function [3]. 
Recently, we demonstrated the efficacy of d/n-ATF5 in a 
bi-transgenic TET-off mouse model in which this construct 
was conditionally induced under regulation of the glial-
fibrillary protein promoter. Expression of d/n-ATF5 caused 
complete regression/eradication of gliomas induced from 
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endogenous progenitor cells and did so without damage 
to normal brain tissue [4]. The basis for the role of ATF5 
in survival of tumor cells is not completely understood, 
but mechanistic studies have suggested that ATF5 supports 
glioblastoma cell survival by regulating expression of the 
anti-apoptotic proteins MCL1 [6] and Bcl2 [13] and of the 
Egr-1 gene [14].
In the present study, we sought to design and test 
a form of d/n-ATF5 that can be effectively delivered to 
glioma cells in the brain. We achieved this by generating 
a truncated, but fully active form of the peptide fused to 
a cell-penetrating domain that permits passage through 
the blood-brain barrier and into intact cells. We report 
that this agent, when delivered systemically to adult mice 
with gliomas generated from endogenous neuro-progenitor 
cells or intracerebral human U87-MG xenografts, causes 
long-term regression/suppression of the tumors as shown 
by MRI and histopathology.
RESULTS
Generation of a cell-penetrating form of d/n-ATF5
Given the successful regression/eradication of 
endogenously-formed gliomas achieved by regulated 
expression of d/n-ATF5 in mouse brain, we devised a 
modified cell-penetrating form of this peptide for systemic 
delivery capable of reaching widely dispersed tumor 
cells through the advantage of rapid biodistribution, 
reduced immune response, with the ability to pass 
through the blood brain barrier into neural cells [4]. Our 
original d/n-ATF5 is an N- terminally truncated form of 
ATF5 that includes the wild-type leucine zipper domain 
with an amphipathic α-helical sequence with leucine 
repeats at every seventh residue replacing the DNA 
binding domain [8]. The enhanced leucine zipper region 
permits interaction with ATF5, but not with DNA, and 
consequently acts as an effective d/n suppressor of ATF5 
actions [8, 15]. N-terminal domain deletion substantially 
stabilizes d/n-ATF5 against degradation [12, 16]. To 
design a deliverable form of d/n-ATF5, we first truncated 
the last 25 amino acids of the protein, which included the 
C-terminal two valine/valine heptad repeats. Structural 
studies suggest that truncation of this region may reduce 
aggregation at body temperatures [17]. Transfection of this 
deleted construct into C6 glioblastoma cells showed equal 
effectiveness as the full length d/n-ATF5 in promoting 
apoptosis (Figure 1; p < 0.05). 
We designed the cell-penetrating form of the 
C-terminally truncated Flag-tagged- d/n-ATF5 (d/n-ATF5-
tr) by N-terminally fusing Flag-tagged d/n-ATF5-tr to a 6x 
histidine repeat, followed by a penetratin sequence (Figure 
2A). Penetratin sequence is a 16-amino acid motif from the 
Antennapedia homeodomain protein permitting passage 
of fused cargos through biological membranes into cells 
[18]. Milligram quantities of the protein (designated Pen-
d/n-ATF5-Recombinant Protein (RP)) were generated by 
expression in bacteria followed by purification by cobalt 
resin affinity chromatography using the 6xHis sequence. 
Figure 1: GFP-d/n-ATF5 C-terminally truncated fusion protein (GFP-d/n-ATF5-Tr) promotes the same level of 
apoptosis as full-length GFP-d/n-ATF5 protein in C6 glioma cells. C6 cells were transfected with pQC-X-I-eGFP, pQC-d/n-
GFPATF5, or pQC-GFPATF5-tr. The percentages (mean ± SEM, n = 4; total of approximately 200 cells scored per condition) of condensed 
apoptotic nuclei in GFP + transfected cells were determined 2 days later. Student’s t-test; GFP+ cells versus GFP-d/n-ATF5+ cells or GFP-
d/n-ATF5-tr cells, (*p < 0.05); GFP-d/n-ATF5+ cells versus GFP-d/n-ATF5-tr cells, (Not Significant). 
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SDS-PAGE showed the purified preparations were more 
than 95% homogeneous with minor species including 
what appeared to be aggregated protein multimers. 
Calculated Mr of Pen-d/n-ATF5-RP with normal bacterial 
removal of the N-formylmethionine is 12,949.18 Da, but 
the major purified product shows an apparent molecular 
mass between 25-28 KDa by SDS-PAGE (Figure 2A). 
Wild type ATF5 and the ATF5 leucine zipper can migrate 
anomalously when subjected to SDS-PAGE [19, 20], and 
high resolution LC-HRMS verified the correct molecular 
weight of Pen-d/n-ATF5-RP while in its solution state. The 
deconvoluted spectra revealed the most abundant form to 
be the predicted 12,948.7 Da monomer, with a low amount 
of dimer at 25,897.5 Da (Figure 2B). Prior studies have 
also shown that recombinant wild type full-length ATF5 
or the bzip domain of ATF5 can form dimers in vitro [19-
21]. Because multi-isomers produced a range of MW of 
the monomer, we elected to use the computed MW of 
13080,which includes the methionine without formyl 
group for our studies. Finally, as a control for Pen-d/n-
ATF5-RP, we generated by similar means a peptide (Pen-
Control-RP) that lacks the d/n-ATF5-tr sequence (Figure 
2A). The purified recombinant control (with a calculated 
molecular mass of 7,099.98 Da) migrated at an apparent 
MW of 7,100 Da by SDS-PAGE (Figure 2A).
Because Pen-d/n-ATF5-RP is designed for systemic 
administration, we showed stability in presence of human 
serum at 37º C with no significant degradation at 8 h and 
a mean loss of 28% of full-length protein by 48 h (Figure 
2C).
Pen-d/n-ATF5-RP rapidly enters and causes 
apoptosis of cultured glioblastoma cells
Before carrying out animal experiments, we verified 
that Pen-d/n-ATF5-RP enters and kills glioblastoma cells 
in culture. When added to serum-containing cultures of rat 
C6 and human U87 glioblastoma cells, both Pen-control-
RP and Pen-d/n-ATF5-RP were readily detectable in the 
cells within 2-4 h and remained detectable for at least 24 
h (Figure 3A, 3B). Confocal microscopy revealed that the 
peptides were present in both the cytoplasmic and nuclear 
compartments (Figure 3A). 
C6 cultures exposed to Pen-control-RP and Pen-
d/n-ATF5-RP were also assessed for apoptotic cell death. 
Pen-Control-RP treated cultures showed background 
levels of apoptotic death similar to that in non-treated 
cultures, whereas cultures treated with Pen-d/n-ATF5-RP 
showed greatly increased numbers of dying cells (Figure 
4; p < 0.05). These actions are similar to what others 
and we have previously reported for multiple rodent and 
human glioblastoma cell lines transfected with d/n-ATF5 
constructs or exposed to ATF5 siRNA [3, 4, 6, 13].
Systemically-delivered Pen-d/n-ATF5-RP crosses 
the blood brain barrier, enters cells and selectively 
triggers rapid, selective apoptotic death of PDGF-
BHA/shp53 induced glioma cells
To test the capacity of Pen-d/n-ATF5-RP to reach 
and treat primary brain tumors, we used a model in which 
gliomas are generated by stereotactic injection of PDGF-
Figure 2: Purity and molecular properties of bacterially expressed and purified 6xhistidine-Flag-Tagged Penetratin-
Flag-D/N-ATF5-tr (Pen-d/n-ATF5-RP) and 6xhistidine-Flag-Tagged Penetratin-Flag-Control (Pen-control-RP) 
peptides. A. Coomassie stained SDS-PAGE of purified Pen-d/n-ATF5-RP and Pen-control-RP (5 µg per lane). Molecular weight markers 
are shown on the left, and a linear scheme of each peptide is shown above each lane. Purification was as described in Methods. B. 
Deconvoluted mass spectra from LC-high Resolution mass spectrometry of purified Pen-d/n-ATF5-RP. The most abundant species is the 
12,948.88 Da monomer form without formyl-methionine followed by the formyl-methionine 13,127 Da monomer form (isoform). The 
spectrum also reveals a small amount of the 25,897.5 Da dimer. C. Stability of Pen-d/n-ATF5-RP in Human Serum. Pen-d/n-ATF5-RP (36 
µM) was incubated with human serum (25% v/v in PBS) at 37º C for 0 to 48 h. Aliquots were withdrawn at various times and the Pen-d/n-
ATF5-RP peptide was resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-Flag antibody. The anti-Flag signal 
was detected by near IR using LiCor software and densitometry of the band at the expected size of Pen-d/n-ATF5-RP and quantified using 
Image J. Values are mean ± SEM, n = 3). 
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Figure 3: Uptake and retention of Pen-d/n-ATF5-RP by cultured glioblastoma cells. A. Confocal images of C6 rat 
glioblastoma cells incubated for 4 hours with either 200 nM Pen-control-RP (left) or Pen-d/n-ATF5-RP (right). Cells were washed, fixed 
and stained with anti-Flag (red) and DAPI (blue). Scale bar = 2 µm. B. Rat C6 and human U87 glioblastoma cells were incubated for the 
indicated times with 3 µM Pen-d/n-ATF5-RP, washed, fixed and immunostained with anti-Flag (green) and DAPI (blue). Scale bar = 5 µm.
Figure 4: Pen-d/n-ATF5-RP promotes apoptosis of C6 glioblastoma cells. C6 cells were treated with 3 µM Pen-d/n-ATF5-RP 
or 3 µM Pen-Control-RP, or were untreated. The percentage (mean ± SEM; n = 4 in 2 independent experiments; approximately 200 cells 
scored) of condensed apoptotic nuclei in cells was determined 5 days later. Student’s t-test; Pen-d/n-ATF5-RP versus Pen-Control-RP cells 
or nontreated, (*p < 0.05); Pen-Control-RP cells versus nontreated cells, (p = 0.29). 
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B-HA/shRNA-p53 retrovirus into the adult mouse brain. 
The tumors are presumably derived from endogenous 
dividing progenitor cells and closely resemble infiltrative 
human gliomas ranging from grades II-IV [4, 22-28]. The 
tumors were detectable as early as 52 days post-injection 
by MRI (see below) and were histologically identifiable by 
the presence of the HA tag as well as by high cellularity, 
hyperchromatic nuclei, and elevated Ki67 staining.
In an initial set of experiments, Pen-d/n-ATF5-RP, 
saline or Pen-Control-RP was delivered intraperitoneally 
to tumor-bearing mice in a single set of four injections 
each of 1 mg/kg at intervals of 1-2 h. The mice were 
sacrificed 16-64 hours after the last injection and the 
fixed brains were stained with anti-Flag antibody to detect 
Pen-d/n-ATF5-RP or with anti-HA to mark PDGF-B-HA 
expressing tumor cells, and for TUNEL to identify dying 
cells. At 16 h, both tumor and normal brain cells (in the 
contralateral hemisphere from the tumor) showed Flag 
staining indicative of extensive uptake of Pen-d/n-ATF5-
RP; there was no signal with saline injection (Figure 5A-
5C). Flag staining was still evident at 40 h after treatment 
and was detectable, though at reduced levels at 64 h 
(Supplementary Figure 1; p < 0.05). While normal brain 
tissue showed no TUNEL staining (Figure 5B), there was 
extensive TUNEL staining within the tumors one day after 
treatment with Pen-d/n-ATF5-RP (Figure 5A). Little or no 
TUNEL signal was observed in tumors of animals treated 
with saline (Figure 5C). Co-localized TUNEL and PDGF-
B-HA+ tumor marker staining continued to be evident 
at 64 h after Pen-d/n-ATF5-RP treatment, but the signals 
indicated cell degeneration and fragmentation (Figure 
5E) compared with cells treated with this peptide for 16 h 
(Figure 5A) or with Pen-Control-RP peptide (Figure 5D). 
To enhance the potential long-term therapeutic 
efficacy of Pen-d/n-ATF5-RP administration in the PDGF-
BHA/p53 mouse tumor model, we devised a treatment 
protocol in which tumor-bearing animals received two sets 
of subcutaneous injections, 5 days apart, each as described 
above. Tumors of mice assessed two days after the second 
treatment (7 days after initial treatment) showed patterns 
of HA and TUNEL staining, that, similar to 64 h after a 
single set of treatments, indicated cell degeneration and 
fragmentation (Figure 5F). 
Full body necropsy of non-tumor bearing animals 
one (n = 2) or two days (n = 2) after completion 
of the above dual treatment regimen revealed no 
evident pathological lesions to internal organs and no 
evident abnormalities of the cerebrum or cerebellum 
(Supplementary Figure 2 and Supplementary Table 1). In 
addition, a liver-kidney serum chemistry panel carried out 
1 day after the second set of Pen-d/n-ATF5-RP injections 
indicated no damage to either organ (Supplementary Table 
1; n = 2)
Systemically delivered Pen-d/n-ATF5-RP 
promotes rapid regression of mouse PDGF-B/
p53 induced gliomas without recurrence and 
suspension of U87-MG/Luciferase xenografts 
growth
We next assessed whether systemic administration 
of Pen-d/n-ATF5-RP promoted prolonged regression of 
gliomas in our mouse model. To achieve this we used 
MRI (post-contrast enhanced 3D FLASH T1 weighted) to 
assess tumors before and at various times after treatment 
with Pen-d/n-ATF5-RP, Pen-control-RP or no treatment. In 
many cases, the tumors were either multifocal or present 
in both hemispheres prior to treatment (Figures 6, 7, 
Supplementary Figures 3, 4). The peptides were injected 
subcutaneously using the two treatment protocol described 
above. Treatments commenced only after the presence of 
tumors was verified by MRI and were randomly assigned. 
As anticipated, in no case did we observe tumor 
regression as assessed by MRI in untreated animals (n 
= 5) or animals treated with Pen-control-RP (n = 4). A 
typical example for an animal treated with control peptide 
is shown in Figure 6. Tumor presence was verified by 
histology on brains of animals that either died or were 
sacrificed after exhibiting moribund behavior or that 
survived beyond the study endpoint (6 months after MRI 
tumor detection). The tumors were HA+ (Figures 6E, 
Supplementary Figure 3), indicating the presence of the 
tagged PDGF-B and exhibited hyperchromatic nuclei 
(Figure 6D) and elevated Ki67 staining typical of gliomas 
(Figure 6F). The infiltrative tumor boundaries matched 
those in the MRI images (Figure 6). 
For mice treated with Pen-d/n-ATF5-RP, 
MRI revealed significant reduction (2/5; Figure 7, 
Supplementary Figure 4) or un-detectability (3/5) of 
tumor signals at 8 days after treatment (the earliest time 
monitored) and full loss of detectable tumor signal within 
3 weeks (n = 7/7). When assessed by MRI at 176-225 days 
after peptide treatment, 7/7 mice assessed were tumor-
free (see for example, Figure 7; Supplementary Figure 4; 
and Figure 8B with p = 0.0002). Thus, Pen-d/n-ATF5-RP 
treatment appeared to rapidly clear gliomas without MRI-
detectable recurrence for at least 6-13 months. 
Postmortem histology (n = 8; 183-392 days 
after treatment; 190-397 days after tumor detection) 
corroborated the MRI findings of tumor regression/
eradication (Figures 7, 8C with a p < 0.0001, 
Supplementary Figure 4). As in the rest of the brain, areas 
that initially had been tumor positive by MRI, showed an 
absence of hyperchromatic nuclei or high cellularity or 
elevated Ki67 staining (Figure 7; Supplementary Figure 
4). There was also no staining (other than scarce scattered 
single cells) for PDGF-B-HA+ (Figure 7; Supplementary 
Figure 4). There were however, foci of GFAP+ cells, 
suggesting glial activation and scarring in the areas where 
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Figure 5: Pen-d/n-ATF5-RP enters the mouse brain and causes targeted apoptosis of glioma cells. A.-F. Representative 
brain sections stained with Flag antibody to indicate presence of Pen-d/n-ATF5-RP or HA to identify presence of tumor-inducing retrovirus 
(red); TUNEL to identify apoptosis (green) and DAPI to localize nuclei (blue). A. Murine brain tumor 24 h post-treatment (16 h after last 
injection) with Pen-d/n-ATF5-RP (52 days post-retrovirus injection). B. Normal contralateral cerebral hemisphere of the same mouse in 
A.. C. Murine brain tumor 24 h post-injection with saline (59 days post-retrovirus injection). Presence of Pen-d/n-ATF5-RP within cells 
is confirmed in the treated mouse A.,B. versus saline control C. by increased Flag antibody staining. Glioma cell-specific induction of 
apoptosis by Pen-d/n-ATF5-RP is illustrated by increased TUNEL staining (green) in A. as compared to B. and C.. D. TUNEL and DAPI 
staining of a tumor-containing brain section 160 days post-retrovirus injection and 3 days after injection of Pen-control-RP. Note HA+ 
cells identifying tumor cells and absence of TUNEL staining. E. Staining as in D. of a tumor-containing section (143 days post-retrovirus 
injection) and 3 days [3D] after Pen-d/n-ATF5-RP treatment. Note the presence of TUNEL staining in HA+ tumor cells and fragmented 
appearance of the staining as compared to A. and D.. F. Staining as in D. of a tumor-containing section 150 days after retrovirus injection 
and 2 days after 2 treatments of subcutaneous Pen-d/n-ATF5-RP injections at seven days [7D] after the first injection. Note the qualitative 
similarity of staining pattern to E. with fragmented PDGF-B-HA and TUNEL staining. Scale bars equal 20 µm.
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tumors had been present (Figure 7; Supplementary Figure 
4).
Human U87-MG-Luc2 xenografts formed 
intracranial tumors that were both intra-cerebral and 
exophytic (extra-cerebral). Subcutaneous (4 mg/kg) Pen-
d/n-ATF5-RP, with scheduling varying from two doses 
at 5 days apart to weekly resulted in either the absence 
or significant loss of volume of intracerebral tumors 
compared to Pen-Control-RP (Supplementary Figure 
5). The exophytic tumors appeared not to be affected 
by either treatment regimen resulting in the absence 
of increased survival time. Cerebrum, with greater 
enriched vascularization, provides an environment 
that both accelerates tumor grow but also results in 
a higher therapeutic bio-distribution for the peptide. 
Extra-cranial environments have potentially poorer 
tumor vascularization resulting in decreased uptake of 
therapeutics. Brain tumor xenografts can have as much as 
50% more vascular network in the brain than subcutaneous 
xenografts for the identical cell line [29-31]. 
Systemically delivered Pen-d/n-ATF5-RP 
promotes survival while maintaining normal 
brain and tissue integrity
All eight retrovirus PDGF-B induced tumor-bearing 
mice treated with Pen-d/n-ATF5-RP survived to the 
nominal 180 day endpoint of the study after detection 
of tumors (Figure 8A; Log-rank (Mantel-Cox) test p = 
0.0194). In contrast, 6/9 control mice died within this 
time. In our past study 40% (n = 16) of mice control” died 
within 180 days of tumor initiation [4]. 
Other than the absence of tumors and the presence 
of glial scarring in areas of prior tumor localization, H&E 
Figure 6: Example of MRI and histopathology of a mouse glioma treated with Pen-Control-RP peptide. A. Post-contrast 
3D FLASH MRI coronal image of the cerebrum of a control mouse that was not injected with PDGF-B-HA/sh-p53 retrovirus. B. Post-
contrast 3D FLASH MRI coronal image of mouse cerebrum showing a bilateral tumor (white contrast) 246 days after PDGF-B-HA/shp53 
retrovirus injection and prior to treatment with Pen-Control-RP peptide. C. Post-contrast 3D FLASH MRI image of the same mouse brain 
40 days after subcutaneous treatment with Pen-Control-RP peptide (as described in the text) reveals persistence of the tumor (arrows). D. 
H&E stained sections of the same mouse brain at tumor-containing areas 1 and 2 shown by arrows in panel C.. The mouse was sacrificed 
116 days after the second treatment with Pen-Control-RP peptide due to moribund behavior. Presence of tumor is indicated in both sections 
by hyperchromatic nuclei and higher cellularity. E. Immunostaining for HA tag in sections from areas 1 and 2 shown in Panel C. reveals 
presence of virally-delivered PDGF-B-HA in induced tumor cells. F. Immunostaining of sections from areas 1 and 2 shown in Panel C. 
reveals a high index of Ki67+/dividing cells indicative of tumor. Scale bars in D-F are 20 µm.
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Figure 7: Pen-d/n-ATF5-RP promotes rapid and long-term regression/eradication of mouse glioma as indicated by 
MRI and histology. A. Post-contrast 3D FLASH MRI scans of a mouse brain before and at various times after treatment (as described 
in text) with Pen-d/n-ATF5-RP. Pretreatment shows image of cortex 243 days after PDGF-B-HA/shp53 retrovirus injection. Yellow arrows 
indicate location of the bilateral tumor. Post-treatment images of the same position of the mouse cortex are at the indicated times after the 
second administration of Pen-d/n-ATF5-RP. Yellow arrows in post-treatment images show location of original tumor. B. H&E image of 
the same mouse brain harvested 192 days after the second Pen-d/n-ATF5-RP treatment. Region 1 represents the location of the section as 
shown in the final time point in A. and at which the tumor was present before treatment. Note the absence of hyperchromatic nuclei and 
higher cellularity that characterize gliomas. C. Ki67 staining in region 2 (from Panel A/176 days post-treatment). Note the absence of 
Ki67+/proliferating cells seen in gliomas. D. HA/DAPI staining of section from region 1. Note the absence of cells expressing exogenous 
PDGF-B-HA. E. GFAP/DAPI staining of section region 1. Note clusters of GFAP+ cells consistent with the presence of a glial scar where 
the tumor was formerly present. Lack of HA staining of a nearby section confirmed the absence of tumor cells. Diagonal green stripes are 
due to tissue folds. Scale bar is 20 µm.
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staining of the brains of the C57BL/6 mice sacrificed 
6-13 months after Pen-d/n-ATF5-RP treatment indicated 
no evident abnormalities and both the subventricular 
and hippocampal subgranular zones appeared normal 
(Supplementary Figure 2). Additionally, the weights of 
the treated C57BL/6 mice prior to sacrifice were either 
within (4/7) or greater than (3/7) one standard deviation 
of the mean weight of age-matched controls given in the 
Mouse Phenome Database at the Jackson Laboratory 
(http://phenome.jax.org/db/q?rtn = strains/details&strainid 
= 7). Two C57BL/6 mice were also subjected to full body 
necropsy at > 6 months of treatment (190 days and 183 
days, corresponding to mice with eradicated tumors in 
Figures 7, and Supplementary Figure 4, respectively). 
No pathological changes were seen in any of the organs 
surveyed (Supplementary Table 1). 
Finally, Pen-d/n-ATF5 is able to promote apoptosis 
in glioma stem cell lines or so-called “tumor-initiating 
cells” [6]. In each case, the population of stem cells 
entered into early (Annexin V +) and late phase apoptosis 
(Annexin V+ and propidium iodide+) with Pen-d/n-ATF5-
RP or chemical synthesized Pen-d/n-ATF5-SYN (lacking 
Flag-tag) compared to recombinant Pen-Control-RP 
(Supplementary Figure 6). 
DISCUSSION
A variety of observations have identified ATF5 as a 
potential target for treatment of malignant gliomas. [3-7, 
32] ATF5 is highly expressed by glioblastoma as well as by 
glioblastoma stem cells; ATF5 expression in glioblastoma 
inversely correlates with prognosis; and interference with 
ATF5 expression or activity causes death of malignant 
glioma cells in vitro and in vivo. To interfere with ATF5 
function, we previously designed and employed a d/n-
ATF5 construct delivered by viral infection, transfection 
or as an inducible transgene. Although this supported the 
potential of ATF5 as a therapeutic target, such a reagent 
was not a practical means to affect ATF5 function in a 
clinically relevant setting. To convert d/n-ATF5 into a 
deliverable therapeutic, we generated a truncated form 
fused to a penetratin cell-penetrating domain. A variety 
of previous studies have supported the potential utility of 
cell-penetrating peptides for therapeutic purposes [18, 33-
35]. Our findings show that Pen-d/n-ATF5-RP enters and 
promotes apoptotic activity in cultured glioblastoma cells, 
including glioma stem cells, and that when systemically 
administered to animals, crosses the blood brain barrier, 
enters brain and tumor cells and causes massive tumor 
cell death and long-term tumor regression/eradication 
Figure 8: Long-term survival and tumor presence outcomes for PDGF-BHA/shp53 glioma-bearing mice treated with 
Pen-d/n-ATF5-RP. A. Survival of glioma (PDGF-B/shRNA-p53 induced)-bearing mice (verified by MRI) with or without treatment with 
Pen-d/n-ATF5-RP (subcutaneous delivery as described in the text). Of the nine control mice, four mice were treated with Pen-Control-RP 
peptide and five were untreated. The experimental endpoint was 200 days after initial tumor detection by MRI. Survival analysis achieved 
by Log-rank (Mantel-Cox) test showed a p-value = 0.0194. B. MRI outcomes for tumor-bearing mice before and after subcutaneous 
treatment with Pen-d/n-ATF5-RP as described in the text. Fisher Exact Match test showed p = 0.0002 with Positive Predictive Value 
95% confidence interval of 0.6306 to 1.000. The latter times range from 176-225 days after tumor treatment (183-230 days after tumor 
detection). C. Brain histopathological outcomes for tumors in control and Pen-d/n-ATF5-RP treated mice. In all cases, MRI verified the 
presence of tumors prior to treatment. Fisher Exact Match test showed p < 0.0001 with Positive Predictive Value 95% confidence interval of 
0.0 to 0.3694. The brains of animals described in A. were harvested either after death (6 controls), after the experimental endpoint (4 Pen-
d/n-ATF5-RP treated animals; 2 Pen-Control or 1 non-Treated animal) or after sacrifice for non-tumor related health problems (2 Pen-d/n-
ATF5-RP treated animals). For treated animals, histological analysis was carried out 260-547 days after tumor initiation (183-392 days after 
Pen-d/n-ATF5-RP administration and 190-397 days after initial tumor detection). Brain sections were prepared as described in Methods and 
were stained with H&E and immunostained for Ki67 and HA (to identify PDGF-B-HA+ tumor cells). The presence/absence of tumors was 
based on observations of hyperchromatic nuclei, high cellularity, elevated Ki67 staining and HA immunostaining.
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without apparent harm to normal tissues. Moreover, the 
demonstration that Pen-d/n-ATF5 as a recombinant or a 
chemical synthetic peptide triggers death in glioma stem 
cells substantiates the potential of its therapeutic potential 
to eradicate both the non-stem cell glioma and the glioma 
stem population to reduce the opportunity of recurrence.
Another key feature of our study was that the 
treated tumor-bearing animals survived for at least 6-13 
months. By contrast, 2/3 of control animals died or 
showed morbidity within 189 days of tumor detection and 
all were tumor positive at death or at the 6-month point. 
Pen-d/n-ATF5-RP regimen for mice with U87-MG-Luc2 
intracranial xenografts revealed smaller volumes or the 
absence of intracerebral tumors. This data are relevant to 
treatment of clinical human spontaneous tumors that do 
not metastasize outside the CNS.
The model in which malignant gliomas were 
induced in adult mice by retrovirally expressed 
PDGF-B and p53 shRNA is derived presumably by 
transformation of PDGF-α-receptor+ neural progenitors 
and oligodendrocyte precursors. Such tumors resemble 
high grade human glioma [4, 22-28] and, like the latter, 
are highly diffuse, relatively large and can invade both 
hemispheres. Given the wide expression of ATF5 in 
human glioblastomas and lower grade gliomas and the 
variety of human and rodent-derived glioblastoma cell 
lines (with and without compromised p53 and PTEN) that 
express and require ATF5 for survival [3, 4, 6, 7], it seems 
likely that a range of malignant glioma cell types will be 
susceptible to cell-penetrating d/n-ATF5.
An important aspect of our study was that although 
Pen-d/n-ATF5-RP promoted regression/eradication/
suppression of tumors, it had no apparent adverse effects 
on normal tissue. While one cannot currently completely 
rule out side effects of the treatment, it is significant that 
treated animals survived without apparent effect for at 
least 6-13 months and that no evident acute or long term 
tissue damage was observed. In addition, any potential 
negative effects of Pen-d/n-ATF5-RP may be mitigated 
by the limited duration of treatment. Because the present 
supplies of bacterially-produced Pen-d/n-ATF5-RP are 
limited, we have not carried out systematic dose-response 
and dosing studies in either glioma animal model. 
Although we focus here on malignant gliomas, it 
is significant to note that ATF5 is expressed by a wide 
variety of carcinomas [32, 36-39], and that culture studies 
have shown apoptotic actions of d/n-ATF5 or ATF5 siRNA 
on tumor cells from a diverse range of tissues. [32, 36, 39, 
40] This raises the possibility that the therapeutic potential 
of cell penetrating forms of ATF5 may not be limited to 
gliomas.
MATERIALS AND METHODS
Retrovirus-induced mouse glioblastoma and U87-
MG xenograft models and treatment with Pen-
d/n-ATF5-RP
As described previously [4], for the retrovirus model 
adult mice were anesthetized and underwent stereotaxic 
injection of retrovirus expressing PDGF-B and p53-
shRNA to generate malignant gliomas. For the xenograft 
model, 10,000 U87 MG-Luc2 cells (PerkinElmer Health 
Sciences Inc.), expressing luciferase were stereotactically 
injected into NOD.Cg-Prkdcscid I/2rgtm1Wjl/SzJ (NSG) 
mice [41]. Analgesics were given immediately after 
surgery. Injected mice were monitored post-surgically 
and throughout the study period, which ranged from 13 
to 519 days. Pen-d/n-ATF5-RP or Pen-Control-RP was 
administered to tumor-bearing animals in treatments of 
four subcutaneous or intraperitoneal injections, spaced 
1-2 hours apart. For the retrovirus model, doses were 1 
mg/kg (200 µl, 0.9% saline) for each injection. In some 
experiments as indicated, dosing was repeated 5 days later. 
Animals injected with 0.9% saline at the same dosing 
schedule and volume served as controls. For the xenograft 
model, Pen-d/n-ATF5-RP or Pen-control-RP doses were 
given one day after the first tumor bioluminescence ( > 106 
photos per sec flux) in one or two subcutaneous injections, 
spaced 1 hour apart.
MRI analysis
Anesthetized (isoflurane and oxygen) mice 
were fitted intravenously with a 30 gauge catheter, and 
positioned head first, prone on the scanner bed.
MRI acquisitions were performed on a Bruker 
Biospec 7 Tesla magnet operating Paravision v5.1 and 
outfitted with a 116-mm diameter gradient with integrated 
shim control. Maximum gradient strength was 450mT/m. 
A cross coil configuration was used for imaging brains and 
a 72-mm ID linear coil was used for RF transmission and a 
4 channel phased array coil for RF reception. Pre-contrast 
and 1 minute post contrast images were acquired with 
FLASH_3Dslab. Gadolinium was injected intravenously 
at a dose of 1µl/g body weight.
FLASH_3Dslab: Fast low angle shot (FLASH) 
images were acquired with TE 6ms, TR 50-ms and a flip 
angle of 30 degrees. Spatial resolution was 0.117-mm 
(read) x 0.117-mm (phase 1) x 0.250-mm (phase 2) with 
a matrix size of 256x128x64. Motion suppression was 
enabled. Two averages were taken giving a scan time of 
13m, 40s. Amide software determined tumor length and 
volume by extracting an elliptic cylinder 3-dimensional 
region of interest from selected voxels. [42].
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Bioluminescence
The NSG mice bearing an U87-MG-luciferase 
xenograft tumor were anesthetized and then 
intraperitoneally injected with 150-µl luciferin (30 mg/
ml; Perkin-Elmer). The injected mice were placed on a 
warmed surface in the IVIS (IVIS100 Perkin-Elmer) 
imaging chamber approximately 3 minutes after injection, 
and were imaged at 6 and 12 min after injection for 
qualitative 2-D surface maps representing concentrations 
of luciferase-expressing tumor cells in the mouse brain. 
Statistical analysis
Student’s t-test was to measure significant 
differences between the different treatments. Kaplan-
Meier survival analysis achieved by log-rank test 
Graphpad Prism 6. 
Ethical approval
The methods were carried out in “accordance” with 
the University of California, Davis approved guidelines 
under IACUC animal use protocols 16123/17735 and 
Biological Use Authorization 740. All experimental 
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Davis under IUCAC animal use protocols 16123/17735 
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